Cargando…
Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study
Objective. To determine the prevalence and risk factors for the recurrence of retinopathy of prematurity (ROP) in Zone II Stage 3+ after ranibizumab treatment. Methods. This was a retrospective, nonrandomized, noncontrolled study that excluded Zone I and aggressive posterior ROP (APROP) cases. Infan...
Autores principales: | Hu, Qinrui, Bai, Yujing, Chen, Xiaoli, Huang, Lvzhen, Chen, Yi, Li, Xiaoxin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401749/ https://www.ncbi.nlm.nih.gov/pubmed/28491468 http://dx.doi.org/10.1155/2017/5078565 |
Ejemplares similares
-
COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY
por: Zhang, Guoming, et al.
Publicado: (2017) -
Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease
por: Menke, Marcel N, et al.
Publicado: (2015) -
Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity
por: Chen, Xuting, et al.
Publicado: (2019) -
Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity
por: Jin, Enzhong, et al.
Publicado: (2019) -
Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity
por: Nicoară, Simona Delia, et al.
Publicado: (2015)